MF59佐剂四价亚单位灭活细胞培养流感疫苗(aQIVc)在50岁及以上成人中的随机2期免疫原性与安全性研究
本研究为随机2期概念验证研究,将≥50岁成人按1:1:1:1随机分配接种aQIVc、无佐剂四价细胞培养流感疫苗(QIVc)、MF59佐剂四价鸡胚流感疫苗(aQIV)或高剂量四价重组流感疫苗(QIVr)。主要目的是通过血凝抑制试验评估接种后28天aQIVc相对各对照疫苗的免疫原性。结果显示aQIVc对全部四株流感病毒的免疫应答高于QIVc和aQIV,对A株应答低于QIVr而对B株高于QIVr;aQIVc耐受良好,未发现安全性问题。
要点
- aQIVc对全部四株流感病毒的免疫应答高于QIVc和aQIV(调整后GMT比值范围1.18-1.85)。
- aQIVc对A株应答低于QIVr(调整后GMT比值范围0.79-0.84),对B株高于QIVr(1.15-1.26)。
- aQIVc耐受良好,未发现安全性问题;这些数据支持在≥50岁成人中进一步研究aQIVc的其他配方。
核心结论
- aQIVc在≥50岁成人中对全部四株流感病毒的免疫应答高于QIVc和aQIV,对A株低于QIVr而对B株高于QIVr。
- aQIVc耐受良好,未发现安全性问题;这些数据支持在≥50岁成人中进一步研究aQIVc的其他配方。
研究设计与样本
- 随机2期概念验证研究,将≥50岁合格参与者按1:1:1:1随机分配接种aQIVc(n=116)、QIVc(n=119)、aQIV(n=116)或QIVr(n=120)。
- 主要目的为通过血凝抑制试验评估接种后28天aQIVc相对各对照疫苗的免疫原性。
主要发现
- 接种后第29天,aQIVc对全部四株流感病毒的免疫应答高于QIVc和aQIV,调整后几何平均滴度(GMT)比值范围为1.18-1.85。
- aQIVc对A株的应答低于QIVr,调整后GMT比值范围为0.79-0.84;对B株的应答高于QIVr,调整后GMT比值范围为1.15-1.26。
- 在≥65岁参与者亚组中,估计的GMT比值总体高于50-64岁参与者。
- aQIVc耐受良好,引起的征集性局部不良事件(AE)发生率与aQIV相似,征集性全身AE发生率略高于aQIV,全部征集性AE发生率高于QIVc和QIVr;未发现安全性问题。
关键数值与推荐
- aQIVc vs QIVc和aQIV:第29天对全部四株流感病毒的调整后GMT比值范围为1.18-1.85。
- aQIVc vs QIVr:对A株的调整后GMT比值范围为0.79-0.84,对B株的调整后GMT比值范围为1.15-1.26。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Influenza poses a significant global healthcare burden, with up to 1 billion infections annually, and poorer outcomes in vulnerable populations such as older adults. Vaccination effectiveness is often lower in elderly individuals. By adding an adjuvant and using cell-based vaccine production methods, the MF59-adjuvanted quadrivalent cell-based influenza vaccine (aQIVc) may boost immunogenicity and vaccine effectiveness in this population. We report the results of a randomised proof-of-concept study, investigating the immunogenicity and safety of aQIVc. Eligible participants aged ≥50 years were randomised 1: 1:1:1 to receive aQIVc (n = 116), a non-adjuvanted quadrivalent cell-based influenza vaccine (QIVc; n = 119), an MF59-adjuvanted quadrivalent egg-based influenza vaccine (aQIV; n = 116), or a high-dose quadrivalent recombinant influenza vaccine (QIVr; n = 120). The primary objective was to assess immunogenicity of aQIVc vs the comparators by haemagglutination inhibition (HI) assay 28 days post-vaccination. Secondary objectives included immunogenicity of aQIVc vs comparators 28 days and 180 post-vaccination by microneutralisation assay and 180 days post-vaccination by HI assay; and reactogenicity and safety of all study vaccines. Compared with QIVc and aQIV, aQIVc elicited a higher immune response (adjusted geometric mean titre [GMT] ratio range 1.18-1.85) against all four influenza strains at Day 29. Against QIVr, aQIVc elicited lower responses against A strains (adjusted GMT ratio range 0.79-0.84), and higher responses against B strains (adjusted GMT ratio range 1.15-1.26). Estimated GMT ratios were generally higher in the subgroup of participants aged ≥65 years vs those aged 50-64 years. aQIVc was well tolerated, eliciting similar rates of solicited local adverse events (AE) and slightly higher rates of solicited systemic AE than aQIV, and a higher rate of all solicited AE than QIVc and QIVr. No safety concern was identified. These data support further investigation of additional formulations of aQIVc in adults aged ≥50 years. Clinical trial registry:NCT04576702.
引用
- Essink BJ, Vermeulen W, Andrade C, et al. A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older. Vaccine. 2025. PMID: 39946829. doi:10.1016/j.vaccine.2025.126791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。